Connor, Clark & Lunn Investment Management (CC&L)’s Moderna MRNA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,300	Closed	-$245K	–	1570
2024 Q1	$245K	Buy	+2,300	New	+$232K	﹤0.01%	1338
2022 Q2	–	Sell	-8,188	Closed	-$1.41M	–	1144
2022 Q1	$1.41M	Sell	8,188 -92,153	-92%	-$15.5M	0.01%	589
2021 Q4	$25.5M	Sell	100,341 -68,562	-41%	-$20M	0.12%	142
2021 Q3	$65M	Sell	168,903 -69,255	-29%	-$25.5M	0.34%	66
2021 Q2	$56M	Sell	238,158 -102,939	-30%	-$18.4M	0.28%	73
2021 Q1	$44.7M	Buy	341,097 +256,641	+304%	+$37.2M	0.25%	87
2020 Q4	$8.82M	Buy	84,456 +21,048	+33%	+$2.13M	0.05%	242
2020 Q3	$4.49M	Buy	63,408 +24,801	+64%	+$1.73M	0.03%	329
2020 Q2	$2.48M	Buy	+38,607	New	+$2.11M	0.02%	415

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MRNA Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,300 shares — an estimated $245K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MRNA in Q2 2020 and held it in 9 quarters. The position peaked at $65M in Q3 2021. 955 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 2,300 Moderna shares in Q2 2024, an estimated $245K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Moderna in Q2 2020 and held it in 9 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Moderna position peaked at $65M in Q3 2021.
955 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.